Combined chemotherapy of ovarian cancer with special reference to carboquone
Sugimori, H.; Kidera, Y.; Matsuyama, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 9(1): 66-71
1982
ISSN/ISBN: 0385-0684 PMID: 6307172 Document Number: 184702
Carboquone (CQ) was administered to 20 patients with ovarian cancer as a main drug in the multiple chemotherapy. Picibanil and Futraful (FT-207) were medicated simultaneously. CQ was given 3 mg each, 2 times a week, up to total 30 mg intravenously or intraperitoneally. 1) The effect of CQ was evaluated in 6 cases. The response was good in 2 cases, fair in 3, and poor in 1. In the other 3 cases after surgery long-lasting remission suggested the effectiveness of this drug. 2) When compared with 43 cases of control group(historical control), apparent higher survival rate was observed until 3 years in this group. 3) Side effects were noted in 89% of the patients. In 5 patients CQ treatment was discontinued because of severe complications. These complications were more pronounced when it was administered intraperitoneally or combined with radiation.